Loading...
The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K(+)-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure
BACKGROUND: CKD is common in heart failure (HF) and associated with morbidity and mortality, yet life-prolonging medications such as renin-angiotensin-aldosterone inhibitors (RAASi) are underused due to risk of hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is a potassium-binding medication tha...
Na minha lista:
| Udgivet i: | BMC Nephrol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8258742/ https://ncbi.nlm.nih.gov/pubmed/34229607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-021-02439-2 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|